Medicinal composition

Abstract

The present invention relates to an ameliorant for improving the movement of the digestive tract comprising, as an active ingredient, 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-2-hydroxymethyl-4-pyrrolidinyl]benzamide or an acid addition salt thereof which is a metabolite of 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-1-ethyl-2-hydroxymethyl-4-pyrrolidinyl]benzamide or an acid addition salt thereof, having high biding affinity for a serotonin receptor 4 (5HT4) and causing no arteritis and thrombus formation; a medicinal composition for improving the movement of the digestive tract comprising the said ameliorant and a pharmaceutically acceptable carrier; and a treating method for promoting the movement of the digestive tract, which comprises using the said medicinal composition for improving the movement of the digestive tract.

Description

TECHNICAL FIELD[0001]The present invention relates to an ameliorant for improving the movement of the digestive tract of a human and an animal containing as an active ingredient a compound which is suitable for activating the movement of the digestive tract, inter alia, stomach to rapidly eliminate abnormal retention of an ingested food in the organ, has a peripheral acting site, and has no side effect such as arteritis, that is, 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-2-hydroxymethyl-4-pyrrolidinyl]benzamide or an acid addition salt thereof, a medicinal composition comprising the active ingredient and a pharmaceutically acceptable carrier, a method for improving disorder of the movement dysfunction of the digestive tract comprising administering a composition containing an effective amount of the active compound to a patient, and use of the compound for preparing the composition.BACKGROUND TECHNIQUE[0002]A compound having a generic name of metoclopramide is widely known as a compound...

AI Technical Summary

Benefits of technology

[0004]The present invention has been made based on the aforementioned findings, and relates to an ameliorant for improving the movement of the digestive tract, which avoids side effect such as arteritis, containing 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-2-hydroxymethyl-4-pyrrolidinyl]benzamide or an acid addition salt thereof as an active ingredient. Further, the present invention relates to a novel medicinal composition for administering to a human or a mammal (e.g. dog, cat, cow, horse, sheep etc.), comprising the 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-2-hydroxymethyl-4-pyrrolidinyl]benzamide or an acid addition salt thereof, and a pharmaceutically acceptable carrier.

[0006]The compound TM161 or an acid addition salt thereof was found out as a metabolite of a 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-1-ethyl-2-hydroxymethyl-4-pyrrolidinyl]benzamide compound or an acid addition salt thereof when administered to a living body, inter alia, a beagle dog and, surprisingly it was made clear in study of the present inventors that the compound or the salt has characteristic capable of avoiding occurrence of side effect such as thrombus formation, arteritis and the like which were concomitantly caused inevitably in administration of 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-1-ethyl-2-hydroxymethyl-4-pyrrolidinyl]benzamide. In addition, it was also made clear that the compound or the salt is superior over TKS159 or an acid addition salt thereof in the ability to improve the movement of the digestive tract. Further, it was also made clear that 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-2-hydroxymethyl-4-pyrrolidinyl]benzamide or an acid addition salt thereof acts as an agonist such that binding with a serotonin 4 (5HT4) receptor is preferential to binding to other receptor, for example, a dopamine D2 receptor.

[0007]Thereby, it has also been elucidated that the compound is a compound which can reduce side effect such as sedative action, extrapyramidal disorder, exacerbation of prolactin secretion and the like which is said to be caused by binding with dopamine D2.

[0008]The present invention has been made based on such the various new findings and, according to the present invention, there are provided an ameliorant for improving the movement of the digestive tract containing as an active ingredient 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-2-hydroxymethyl-4-pyrrolidinyl]benzamide or an acid addition salt thereof, which has high binding affinity for a serotonin receptor 4(5HT4), and can avoid occurrence of side effect such as thrombus formation, arteritis and the like inevitably caused concomitantly in administration of 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-1-ethyl-2-hydroxymethyl-4-pyrrolidinyl]benzamide or an acid addition salt thereof, and a medicinal composition containing the same as an active ingredient, and a pharmaceutically acceptable carrier. Since it is an indispensable attribute for a medicinal composition that side effect is avoided as much as possible, the present invention is meaningful.

[0011](1) an ameliorant for improving the movement of the digestive tract comprising as an active ingredient 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-2-hydroxymethyl-4-pyrrolidinyl]benzamide or an acid addition salt thereof, which has high binding affinity for a serotonin receptor 4 (5HT4), and does not cause arteritis and thrombus formation,

Problems solved by technology

After all, occurrence of such disorders truly shows that TKS159 is not suitable for use as a medicine.

It is widely known that there are many cases where although a drug has sufficient required action, since occurrence of a few unavoidable not preferable actions can not be avoided, it could not actually play a role as a therapeutic drug.

Images